Cargando…
Vaccines for COVID‐19
Since the emergence of COVID‐19, caused by the SARS‐CoV‐2 virus at the end of 2019, there has been an explosion of vaccine development. By 24 September 2020, a staggering number of vaccines (more than 200) had started preclinical development, of which 43 had entered clinical trials, including some a...
Autores principales: | Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.‐M., Pierce, B. F., Stirling, D. C., Wang, Z., Pollock, K. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597597/ https://www.ncbi.nlm.nih.gov/pubmed/32935331 http://dx.doi.org/10.1111/cei.13517 |
Ejemplares similares
-
Determining the Longitudinal Serologic Response to COVID-19
Vaccination in the Chronic Kidney Disease Population: A Clinical Research
Protocol
por: Yau, Kevin, et al.
Publicado: (2023) -
Acute Kidney Injury and Renal Replacement Therapy in COVID-19 Versus Other Respiratory Viruses: A Systematic Review and Meta-Analysis
por: Cau, A., et al.
Publicado: (2021) -
The Impact of COVID-19 on Patients With ADPKD
por: Kutky, Meherzad, et al.
Publicado: (2021) -
COVID-19 Vaccine Effectiveness Among Patients With Maintenance Dialysis; Observations From Population Level Cohort Studies in 2 Large Canadian Provinces
por: Atiquzzaman, Mohammad, et al.
Publicado: (2023) -
COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases
por: Baker, D., et al.
Publicado: (2020)